The Impact of Early Versus Late Platelet and Neutrophil Recovery After Induction Chemotherapy On Survival Outcomes Of Patients With Acute Myeloid Leukemia
The prognosis of patients with acute myeloid leukemia (AML) is affected from the factors that are both patient and disease specific. The aim of this study is to evaluate the impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of acute myeloid leukemia patients. One hundred and eighty one patients with AML who were treated in our tertiary center between the years of 2001 and 2018 were evaluated. Neutrophil (NRT) and platelet recovery times (PRT) were accepted as the periods from the beginning of induction chemotherapy to a neutrophil count ≥0.5×109/L and a platelet count ≥20×109/L, 3 days in a row, respectively. The median time of platelet recovery was 25 day (12-52) for all patients. Therefore, in the first 25 days platelet recovery was defined as early platelet recovery (EPR) and ≥26 days was defined as late platelet recovery (LPR). The median time to neutrophil recovery was 28 day (13-51) for all patients. Therefore, in the first 28 days neutrophil recovery was defined as early neutrophil recovery (ENR) and ≥29 days was defined as late neutrophil recovery (LNR). The 5-year OS for patients who had EPR and who had LPR after induction chemotherapy were 62% and 23%, respectively (p<0.001). The 5-year DFS for patients who had EPR and who had LPR after induction chemotherapy were 57% and 15%, respectively (p<0.001). In conclusion, the short bone marrow recovery time may indicate a better healthy hematopoiesis/marrow capacity associated with longer OS and DFS.